At a glance
- Originator Bayer
- Class Analgesics; Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 20 May 1999 Discontinued-Preclinical for Hyperlipidaemia in Germany (Unknown route)